Type 2 diabetes

Overview

Type 2 diabetes is a progressive disorder defined by the combination of insulin resistance and progressive beta-cell failure, producing chronic hyperglycaemia and its microvascular, macrovascular and neuropathic complications. It accounts for around 90% of all diabetes. An estimated 13% of US adults have diabetes and 34.5% meet criteria for prediabetes; prevalence rises with age.^[4]

The disease is usually detected by screening or incidentally years after onset, because hyperglycaemia is silent until complications appear. Early detection matters: simulation modelling of the ADDITION-Europe trial showed the intensity of glucose, blood pressure and cholesterol treatment after diagnosis is less important than the time of its initiation — a 3-year diagnostic delay forfeits a 29% relative reduction in cardiovascular risk that prompt treatment would have delivered.^[5]

Management is a lifelong cycle of lifestyle foundation, metformin-based pharmacotherapy escalated on individualised HbA1c targets, comorbidity-driven cardiorenal protection, and annual complication surveillance. The landmark trials of the last decade shifted the treatment goal from glucose alone to organ protection: empagliflozin reduced cardiovascular death by 38%, liraglutide reduced it by 22%, and canagliflozin cut kidney-failure progression by a third — benefits that are independent of the drugs' glucose-lowering effect.^[12][14][20]

References37ShowHide

1. [1]American Diabetes Association Professional Practice Committee 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025 Diabetes Care, 2025.PMID 39651986
2. [2]International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes Diabetes Care, 2009.PMID 19502545
3. [3]Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values Diabetes Care, 2008.PMID 18540046
4. [4]US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement JAMA, 2021.PMID 34427594
5. [5]Sussman JB, Hayward RA, Choi H, et al. Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the ADDITION-Europe Trial Diabetes Care, 2015.PMID 25986661
6. [6]UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet, 1998.PMID 9742976
7. [7]UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet, 1998.PMID 9742977
8. [8]Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med, 2008.PMID 18784090
9. [9]Holman RR, Coleman RL, Chan JCN, et al. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91) Lancet, 2024.PMID 38772405
10. [10]Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia, 2022.PMID 36151309
11. [11]Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review JAMA, 2014.PMID 25536258
12. [12]Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes N Engl J Med, 2015.PMID 26378978
13. [13]Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med, 2019.PMID 30415602
14. [14]Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med, 2016.PMID 27295427
15. [15]Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med, 2016.PMID 27633186
16. [16]Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet, 2019.PMID 31189511
17. [17]Nathan DM, Lachin J, Balasubramanyam A, et al. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes N Engl J Med, 2022.PMID 36129996
18. [18]Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes N Engl J Med, 2021.PMID 34170647
19. [19]Perkovic V, Tuttle KR, Rossing P, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes N Engl J Med, 2024.PMID 38785209
20. [20]Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med, 2019.PMID 30990260
21. [21]McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction N Engl J Med, 2019.PMID 31535829
22. [22]Lasserson DS, Glasziou P, Perera R, et al. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses Diabetologia, 2009.PMID 19644668
23. [23]Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med, 2003.PMID 12556541
24. [24]Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (ADVANCE) Lancet, 2007.PMID 17765963
25. [25]ACCORD Study Group, Ginsberg HN, Elam MB, et al. Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med, 2010.PMID 20228404
26. [26]Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes N Engl J Med, 2013.PMID 23796131
27. [27]Lean MEJ, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial Lancet, 2018.PMID 29221645
28. [28]Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 24-month results from the DiRECT open-label, cluster-randomised trial Lancet Diabetes Endocrinol, 2019.PMID 30852132
29. [29]Riddle MC, Cefalu WT, Evans PH, et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes Diabetes Care, 2021.PMID 34462270
30. [30]Pasquel FJ, Umpierrez GE Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment Diabetes Care, 2014.PMID 25342831
31. [31]Dhatariya KK; Joint British Diabetes Societies for Inpatient Care The management of diabetic ketoacidosis in adults - An updated guideline from the Joint British Diabetes Societies for Inpatient Care Diabet Med, 2022.PMID 35224769
32. [32]Cardona Z, Friedman JG, Kamal N, et al. Developing a Protocol for Management of Euglycemic Diabetic Ketoacidosis Curr Diab Rep, 2025.PMID 40900206
33. [33]Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association Diabetes Care, 2017.PMID 27999003
34. [34]Mogilevskaya M, Gaviria-Carrillo M, Feliciano-Alfonso JE, et al. Diagnostic Accuracy of Screening Tests for Diabetic Peripheral Neuropathy: An Umbrella Review J Diabetes Res, 2024.PMID 39664106
35. [35]Schaper NC, van Netten JJ, Apelqvist J, et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) Diabetes Metab Res Rev, 2024.PMID 37243927
36. [36]Inkster B, Frier BM Diabetes and driving Diabetes Obes Metab, 2013.PMID 23350766
37. [37]Li M, Liu J, Sun P, et al. Risk factors for hypoglycemia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis Front Endocrinol (Lausanne), 2026.PMID 42620370